PT - JOURNAL ARTICLE AU - Karthik Ramasamy AU - Ross Sadler AU - Sally Jeans AU - Paul Weeden AU - Sherin Varghese AU - Alison Turner AU - Jemma Larham AU - Nathanael Gray AU - Oluremi Carty AU - Joe Barrett AU - Stella Bowcock AU - Udo Oppermann AU - Gordon Cook AU - Chara Kyriakou AU - Mark Drayson AU - Supratik Basu AU - Sally Moore AU - Sarah McDonald AU - Sarah Gooding AU - Muhammad K Javaid TI - Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response AID - 10.1101/2021.10.21.21265158 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.21.21265158 4099 - http://medrxiv.org/content/early/2021/10/25/2021.10.21.21265158.short 4100 - http://medrxiv.org/content/early/2021/10/25/2021.10.21.21265158.full AB - Background Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination.Methods Using a prospective study of myeloma patients in UK Rudy Study cohort, we assessed humoral and Interferon gamma release assay (IGRA) cellular immune responses to COVID-19 vaccination post second COVID-19 vaccine administration.Findings We report data from 214 adults with myeloma (n=204) or smouldering myeloma (n=10) who provided blood samples at least 3 weeks after second vaccine dose. Positive Anti-Spike antibody levels (> 50 IU/ml) were detected in 189/203 (92.7%), positive IGRA responses were seen in 97/158 (61.4%) myeloma patients. Only 10/158 (6.3%) patients were identified to have both a negative IGRA and negative Anti-Spike protein antibody response. 95/158 (60.1%) patients produced positive results for both anti-Spike protein serology and IGRA. After adjusting for disease severity and myeloma therapy, poor humoral immune response was predicted by male gender. Predictors of poor IGRA included anti-CD38/ anti-BCMA therapy and Pfizer-BioNTech (PB) vaccination.Interpretation Significant majority of myeloma patients elicit Anti-Spike protein antibody responses to COVID-19 vaccine with 60% of myeloma patients showing both humoral and T cell response. Predictors of a poor immune response included male gender, myeloma therapy regimen and administration of Pfizer-BioNTech vaccination. Further work is required to understand the clinical significance of divergent cellular response to vaccination.Funding Funding for this study has been received from Blood Cancer Vaccine Consortium and Janssen UK. RUDY platform has been funded by NIHR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: Funding for this study has been received from Blood Cancer Vaccine Consortium and Janssen UK. RUDY platform has been funded by NIHR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval: The study is based on the existing RUDYstudy.org platform (LREC 14/SC/0126 & RUDY LREC 17/SC/0501), an established online rare disease platform with online dynamic consent and patient reported outcome assessments. IRAS no: 213780, RUDY study Minor amendment 3, HRA approval 28th January 2021 given by NHS HRA South Central - Berkshire B Research Ethics Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript